Learn how our investigational therapies work

1. Engineer

2. Shield

3. Prepare

4. Place

5. Produce

  • 1 Engineer

    Our investigational therapies start with human cells engineered to produce therapeutic molecules that may be missing or deficient in the body, including proteins, antibodies and hormones.

  • 2 Shield

    We then put the cells into tiny spheres, which were designed to do two things:

    • Shield the cells from an immune response
    • Allow the inflow of nutrients and outflow of a specific therapy
  • 3 Prepare

    Here’s what a potential dose could look like. For purposes of this visualization, we have colored the spheres blue, but in reality, they are clear.

  • 4 Place

    For our clinical studies, a doctor will place the spheres into the patient’s abdomen via a minimally invasive procedure. The cells are designed to live where they are placed, producing the specific protein the patient needs, which can then circulate throughout the body.

  • 5 Produce

    We believe that a single dose of our SLTx product candidates may provide a meaningful long-term clinical benefit to patients, and our technology allows us to re-dose, if necessary.

We Care

At Sigilon, we care deeply about patients and caregivers; they are at the center of what we do and how we act. Below are some recent ways Sigilon and its’ employees have shown their commitment to the communities we hope to serve.

Serving the community